Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhib...
Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor
About this item
Full title
Author / Creator
Liu, Baojie , Lu, Yongzheng , Lin, Ruihui , Xu, Junbao , Shang, Zilin , Hou, Xinyu , Shao, Xulong , Pan, Zhifang , Yu, Tao and Feng, Weiguo
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
ABCB1 overexpression is a key factor in causing multidrug resistance (MDR). As a result, it is crucial to discover effective medications against ABCB1 to overcome MDR. Falnidamol, a tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR), is currently in phase 1 clinical trials for the treatment of solid tumors. In thi...
Alternative Titles
Full title
Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8098216d79a44c00987806475fb8a93b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8098216d79a44c00987806475fb8a93b
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-024-13371-7
